Anthera Pharma (ANTH) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Anthera Pharmaceuticals Reports 2015 First Quarter and Operational Update
May 11, 2015 5:30 PM EDTCompleted Interim Analysis from Phase 3 Trial with Blisibimod for Systematic Lupus Erythematosus Completed Interim Analysis from Phase 2/3 Trial with Blisibimod for IgA Nephropathy Increased Cash Position by $43 Million Through Equity Investment by Zenyaku and Equity Offering Received $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Phase 3 Development of Sollpura (liprotamase)
HAYWARD, Calif., May 11, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced financial results and an operational update for the first quarter ended March 31, 2015.
Net loss for the quarter ended March 31, 2015 was $7.7 million, compared to... More
